10-Q quarterly report · filed Oct 28, 2026

MIMEDX GROUP, INC. (MDXG) Q3 2026 10-Q Quarterly Report

Short answer

MIMEDX GROUP, INC. (MDXG) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $62M (down 45.2% year over year) with net income of −$9M.

Q3 2026 key financials · XBRL

Revenue
$62M
−45.2% YoY · −3.2% QoQ
Net income
−$9M
−151.8% YoY · +41.5% QoQ
Operating margin
-18.8%
Gross margin
79.8%
EPS (diluted)
−$0.06
−154.5% YoY · +40.0% QoQ

Source: XBRL data from the MIMEDX GROUP, INC. (MDXG) Q3 2026 10-Q on SEC EDGAR. USD.

MIMEDX GROUP, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $62.3M, down 45.2% YoY from $113.7M
  • Gross margin 79.8% vs 83.5% YoY, pressured by Wound pricing and unfavorable mix
  • Best segment Surgical revenue $40.0M, up 9.1%; worst Wound revenue $22.3M, down 71.0%
  • Net cash $120.8M, up $2M sequentially; operating cash used $4.2M through nine months
  • Near-term headwinds: Medicare reimbursement changes and FTC Second Request delaying Sanara acquisition clearance

Risk Factors

  • New regulatory risk: FTC Second Request received October 15, 2026, potentially extending HSR waiting period 30 days after substantial compliance
  • New transaction risk: Sanara acquisition could face FTC-imposed conditions, restrictions, or prevention, reducing anticipated benefits
  • New financing risk: Hayfin Term Loan availability depends on commitment conditions, with alternative financing potentially costlier
  • New leverage risk: Expected Hayfin Term Loan may increase debt service and restrict additional borrowing, investments, dividends, and asset sales
  • New operational risk: Acquisition-related review and integration could divert management resources and disrupt employees, customers, and business relationships

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other MIMEDX GROUP, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.